Journal article
CYP1A1 and GSTM1 polymorphisms and oral cancer risk
Cancer epidemiology, biomarkers & prevention, Vol.6(10), pp.791-797
10/1997
Handle:
https://hdl.handle.net/2376/115173
PMID: 9332761
Abstract
The importance of both the CYP1A1 exon 7 (ile:val) and GSTM1 (0/0) polymorphisms in oral cancer susceptibility was assessed by examining polymorphic prevalences in 135 patients with oral cancer and 135 noncancer controls frequency-matched by age at diagnosis (+/- 5 years), race, sex, and institute of patient recruitment. The prevalence of the GSTM1 (0/0) genotype was approximately 51% in both cases and controls. The prevalence of the CYP1A1 (ile:val) polymorphism [including both the (ile/val) and (val/val) genotypes] was significantly higher in cases as compared to controls (17.6% versus 7.6%, respectively; crude odds ratio, 2.6; confidence interval, 1.2-5.7). No association was observed between polymorphic prevalence and levels of smoking or alcohol consumption in cases. These results suggest that the GSTM1 null genotype is not associated with oral cancer risk. These results also suggest that individuals with the CYP1A1 exon 7 ile:val polymorphism are at increased risk for oral cancer, and that this risk may not be influenced by differences in exposure to tobacco smoke.
Metrics
9 Record Views
Details
- Title
- CYP1A1 and GSTM1 polymorphisms and oral cancer risk
- Creators
- J Y Park - Department of Pathology, School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, USAJ E MuscatQ RenS P SchantzR D HarwickJ C SternV PikeJ P Richie, JrP Lazarus
- Publication Details
- Cancer epidemiology, biomarkers & prevention, Vol.6(10), pp.791-797
- Academic Unit
- Pharmaceutical Sciences, Department of
- Publisher
- United States
- Grant note
- F32 CA073173 / NCI NIH HHS CA59917 / NCI NIH HHS R01 CA059917 / NCI NIH HHS F32 CA073173-01A1 / NCI NIH HHS
- Identifiers
- 99900547871901842
- Language
- English
- Resource Type
- Journal article